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Objective: To evaluate usefulness of non-physician health workers (NPHW) to improve
adherence to medications and lifestyles following acute coronary syndrome (ACS).
Methods: We randomized 100 patients at hospital discharge following ACS to NPHW inter-
vention (n = 50) or standard care (n = 50) in an open label study. NPHW was trained for
interventions to improve adherence to medicines – antiplatelets, b-blockers, renin–angio-
tensin system (RAS) blockers and statins and healthy lifestyles. Intervention lasted 12
months with passive follow-up for another 12. Both groups were assessed for adherence
using a standardized questionnaire.
Results: ST elevation myocardial infarction (STEMI) was in 49 and non-STEMI in 51, mean age
was 59.0  11 years. 57% STEMI were thrombolyzed. On admission majority were physically
inactive (71%), consumed unhealthy diets (high fat 77%, high salt 58%, low ﬁber 57%) and 21%
were smokers/tobacco users. Coronary revascularization was performed in 90% (percutaneous
intervention 79%, bypass surgery 11%). Drugs at discharge were antiplatelets 100%, b-blockers
71%, RAS blockers 71% and statins 99%. Intervention and control groups had similar char-
acteristics. At 12 and 24 months, respectively, in intervention vs control groups adherence
(>80%) was: anti platelets 92.0% vs 77.1% and 83.3% vs 40.9%, b blockers 97.2% vs 90.3% and
84.8% vs 45.0%), RAS blockers 95.1% vs 82.3% and 89.5% vs 46.1%, and statins 94.0% vs 70.8% and
87.5% vs 29.5%; smoking rates were 0.0% vs 12.5% and 4.2% vs 20.5%, regular physical activity
96.0% vs 50.0%, and 37.5% vs 34.1%, and healthy diet score 5.0 vs 3.0, and 4.0 vs 2.0 ( p < 0.01 for
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all). Intervention vs standard group at 12 months had signiﬁcantly lower mean systolic BP,
heart rate, body mass index, waist:hip ratio, total cholesterol, triglyceride, and LDL cholesterol
(p < 0.01).
Conclusions: NPHW-led educational intervention for 12 months improved adherence to evi-
dence based medicines and healthy lifestyles. Efﬁcacy continued for 24 months with attrition.
# 2016 Cardiological Society of India. Published by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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In India, compared to high and middle income countries, a
greater mortality from cardiovascular diseases (CVD) has been
reported despite having lower cardiovascular risk factors and
younger age.1 This could be due to inadequate control of CVD
risk factors, poor management of acute coronary events, poor
secondary prevention or a combination of all the three.2
Although there have been some improvements in acute
coronary care in developing countries,3 including India,4
current data indicate a higher mortality among such patients
in India5,6 compared to studies from developed countries.7,8
International cohort and population-based studies have
shown that greater adherence to cardioprotective drug regi-
mens following acute coronary syndromes (ACS) is associated
with lower long-term mortality.9–12 Adherence to evidence
based cardioprotective medication in particular to antiplate-
lets, b-blockers, renin–angiotensin system (RAS) blockers such
as angiotensin converting enzyme inhibitors (ACEI) or angio-
tensin receptor blockers (ARB), and statins following hospital
discharge for ACS has been found to be poor worldwide.9While
Indian registries have reported adequate use of various
secondary preventive medicines at hospital discharge,5,6
studies have reported that their use in the community is
low.13–15 In the Prospective Urban Rural Epidemiology (PURE)
study, the long term use of secondary prevention therapies
was suboptimal in India and other South Asian countries and
at a mean of 4.5 years after diagnosis of coronary heart disease
(CHD) and more than 80% of patients were not on any effective
secondary prevention drugs.16 PURE study also reported that
only 38% in low and middle income countries had quit
smoking compared to 75% in high-income countries and 26%
consumed healthy diets compared to 43% in high income
countries at the end of 4.5 years.17 On the other hand,
increasing trends in use of secondary preventive lifestyles and
drugs have been reported in EUROSPIRE studies.18
Interventions led by community health workers (CHW) or
non-physician health workers (NPHW) have improved adher-
ence to drug therapies in communicable diseases, e.g.,
tuberculosis, HIV/AIDS, etc., with considerable success in
high-, middle- as well as low-income countries.19 The utility of
trained CHWs or NPHWs has been demonstrated in non-
communicable diseases (NCDs) management in developed
countries but has not been adequately evaluated in developing
countries.20 The aim of the present study was to assess
whether a trained NPHW can improve adherence to proven
secondary prevention measures after an ACS event. We
performed an open label prospective randomized controlled
multisite trial to assess the effect of NPHW based educationalintervention among patients and their family members for
12 months to improve adherence to cardioprotective medica-
tion and lifestyle modiﬁcations (LSM) vs usual care for ACS
survivors following hospitalization.21 In the present study we
evaluated the effect of this intervention at 24-months using a
passive follow-up of all such patients at our center.
2. Methods
This study was conducted after approval by the institutional
ethics committee at the hospital. Written informed consent
was obtained from each study participant. Patients with ACS,
as the primary reason for admission during the years 2011–
2012, were screened for eligibility. ACS was deﬁned as either
myocardial infarction (ST elevation or non-ST elevation) or
unstable angina using standard deﬁnitions.5 We excluded
patients living far (>50 km) from the healthcare facility and
those unlikely to survive the study duration due to other
serious illnesses, e.g., metastatic cancer, or inability to execute
study protocol, lack of telephone or cellphone and pregnancy.
The principal multisite study was performed at 12 centers in
the country and detailed methodology has been reported
earlier.21,22 The follow-up duration in the national study was
12 months.22
Eligible patients with ACS were consecutively randomized
using centralized process with a telephone randomization
service at national coordinating center in a 1:1 ratio to
intervention or standard care arm. The allocation sequence
was concealed until a patient consented to participate. All
screened hospitalized ACS patients for study were coun-
selled to participate in the study 1–2 days before discharge
from hospital and written informed consent obtained form
those who agreed to participate. The care provider (spouse or
another family member) of each patient was involved in the
decision to participate in the study. Patients in both groups
received all standard ACS hospital discharge counselling by
the admitting physician and other staff. This included
follow-up appointments, diet and exercise advice, discharge
medication list and educational information about cardiac
medications.
For the intervention group, we trained a NPHW to provide
follow-up care. Criteria for selection of NPHW were – young
male or female with schooling to higher secondary level (12th
grade education) and no formal college degree, good commu-
nication skills and proﬁciency in local languages, some
knowledge of English and familiarity with a hospital set-
ting.21,22 These criteria were used to facilitate use of similarly
available persons (CHW) in the national health program for
chronic diseases in India (National Programme for Cancer,
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Each NPHW was provided training at the local hospital by a
project manager known as SPREAD Project Ofﬁcer (SPO). This
SPO was a graduate with background in medical sciences
(pharmacist, nurse, non-postgraduate medical degree or
practitioners of other systems of medicine) with competence
inter-personal communications. He was trained at national
coordinating center for 3 days and also helped in developing a
comprehensive NPHW training manual. He trained the NPHW
over a 6-month period. Periodic evaluation of NPHW and SPO
was performed. Other details have been reported previously.21
The NPHW was intimately involved with the patient and
his family and carried out formal discussions and building of
rapport with the patient and the family care provider in the
initial visit. At this stage the NPHW, caregiver and the patient
mutually identiﬁed potential barriers to compliance with
healthy lifestyle and pharmacological treatment and devel-
oped strategies to overcome them. Tools used for improving
adherence were a visual calendar and a health diary. We
focused on importance of evidence based drugs and healthy
lifestyles. For patients randomized to intervention arm follow-
up visits were explained with the role and objectives of NPHW
over 12 months follow-up. Patients and care-providers were
urged to collect empty medication blisters regularly and this
was veriﬁed by the NPHW at each visit. At the ﬁrst visit during
discharge, the NPHW and patient mutually decided on the
schedule for the follow-up visits over one year.
2.1. Interventions and follow up
There were a total of 6 follow-up visits in the intervention
arm, four at the hospital at 1, 5, 7, and 12 months and two
home visits at 3 and 9 months. Home visits were ﬁxed at
mutually convenient times when the home caregiver was
also available. The key intervention was to have a relaxed
discussion over 45–60 min with the patient and the primary
caregiver. At this time the NPHW helped to identify barriers
for medication adherence (lack of knowledge, attitude
regarding medications, cost, access, regimen complexity,
side effects and lack of family support) and for making
adequate LSMs (lack of knowledge, unfavorable environ-
ment, lack of family support).21 Thereafter the NPHW and
patient with the caregiver mutually evolved strategies to
overcome the barriers. The interventions were therefore
personalized for each patient.22 At each visit NPHWs
assessed risk factors such as blood pressure (BP), tobacco
and alcohol use, diet, exercise and adherence to secondary
prevention medications that were prescribed. They also
veriﬁed entries in the visual calendar, empty blisters counts
and patient diary to corroborate the oral report from
patients and their caregivers. Details of correlation of these
parameters for the national study have been reported
earlier.22 During home visits, in addition to the activities
at hospital visits, the NPHW involved as many family
members as possible in discussions related to the care of
the patient, speciﬁcally in reviewing the barriers for
adherence to medication and lifestyle. At the end of the
home visit, the NPHW reviewed the patients' medication
adherence, BP and general condition. If the status was
unsatisfactory, the NPHW also contacted the treatingphysician directly for necessary medical advice. In between
visits the patient was encouraged to call the NPHW for any
health related issue. Furthermore the NPHW made a
telephone call every 3 months to inquire on their health
status as well as their adherence to medications and LSMs
advice. At the ﬁnal visit the NPHW gave the patient and the
caregiver a summary of their adherence level to medications
and LSM over the preceding year and advised them to
continue regular follow-up with their treating physician.
Patients in the standard care group followed treatments in
accordance with the hospital's usual practice. At the end of
12-month follow-up the standard care patients had data
obtained on adherence to medications and LSM advice over
the last one-month and whether any events occurred over
the course of the study. If the patient had died, these details
were collected from the caregiver. For the next 12 months no
contact was maintained by the patient with NPHW and he
was provided usual care by the physicians. Details of
adherence was inquired at the end of 24 months using
the tools reported above.
2.2. Study outcomes
The main study outcome was the adherence to secondary
prevention medications and LSMs at 12 months and
secondary outcome was adherence at 24 months. We
estimated adherence to medications using data regarding
each of the four types of medications (anti-platelets,
b-blockers, RAS inhibitors, and statin) as well a composite
medication adherence score (CMAS).23 The adherence as
well as CMAS was calculated for these four types of
medications at one month preceding the ﬁnal follow-up
visit at 12 and 24 months. The CMAS is the proportion of all
these four medication taken of those prescribed in the last
one month. In case the physician stopped a drug sometime
during the preceding month, this drug was not considered in
the calculation. Patients who took 80% or more of all the
prescribed drugs were categorized as adherent. To assess
LSM we used patient self-reports and primary caregiver
reports for tobacco consumption or smoking. At the one year
follow-up visit, patients initially categorized as 'current'
consumers were reclassiﬁed as 'former' if they quit tobacco
at least one month prior to the ﬁnal visit. Exercise was
classiﬁed as none/sedentary or moderate. Diet was assessed
with a simple 5-point questionnaire and a score was
computed using weekly consumption of vegetables and
fruits, whole grain and high ﬁber foods, sweets, reﬁned
grains, deep fried and salty foods and red meat.21 Higher
scores indicated a healthier diet. At 24 month, patients were
contacted telephonically to assess drug adherence and
lifestyles. Details of all deaths, cause of deaths and number
of hospitalization were also obtained in both the groups.
2.3. Statistical analyses
The primary outcome in the study was adherence to
prescribed cardioprotective medications (antiplatelets, b
blockers, RAS blockers and statins) based on visual calendar
marking. Other methods considered were counting of pills
or self report but were not used because of patient
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 8 3 2 – 8 4 0 835resistance on qualitative study.21 We estimated that
100 patients (50 patients in each group) would have
sufﬁcient power to detect improvement of ≥15% in drug
adherence in the intervention arm relative to the usual care.
This sample size has 90% power with alpha of 5%. Power was
estimated based on prior studies that demonstrated that
50–70% of patients will be adherent at 12 months after
discharge from hospital.23–25 Even with 10% loss in follow-
up, there will still be 90 patients (45 patients in each group)
at the end of study, which is sufﬁcient to assess the primary
outcome. All analyses were performed according to the
intention to treat principle using a commercially available
software (SPSS, Version 13.0, SPSS Inc., Chicago). Between-
group comparisons of continuous variables were performed
by t-test and categorical variables with x2 test. We comparedTable 1 – Baseline demographic and clinical characteristic of st
Control g
Demographic variables
Mean age (years) 60.7 
Time from symptom onset to hospital, median (IQR) 7.0 (
Distance of residence to hospital (km) 19.6 
Diagnoses
Unstable angina 18 (3
Non ST elevation myocardial infarction 11 (2
ST elevation myocardial infarction (STEMI) 21 (4
Thrombolysed STEMI's 12 (5
Lifestyle risk factors
Smoking/tobacco use 11 (2
High fat diet 40 (8
High salt diet 31 (6
High calorie diet 25 (5
Low ﬁber diet 29 (5
Low fruits/vegetables intake 27 (5
Physically inactive 40 (8
Risk factors
Hypertension 28 (5
Diabetes mellitus 12 (2
Known dyslipidemia 4 (8
Family history of coronary artery disease 7 (1
Prior cardiovascular events 5 (1
Previous coronary intervention 5 (1
Medication taken in the month prior to hospitalization
Antiplatelets 6 (1
Anti-hypertensive 25 (5
Anti-diabetics 10 (2
In-hospital treatments
Coronary interventions (PCI or CABG) 43 (8
PCI 36 (8
CABG 7 (1
Medical only 7 (1
Medications at discharge
Aspirin 50 (1
RAS blockers 33 (6
b blocker 37 (7
Lipid lowering 50 (1
Diuretics 11 (2
Calcium channel blockers 4 (8
IQR, interquartile range; PCI, percutaneous coronary interventions; CABG
a p values determined by x2 test unless mentioned.
b t-Test.
c Wilcoxon test.continuous variables which were not normally distributed
with the Wilcoxon test. p value <0.05 was considered
signiﬁcant.
3. Results
We randomized 100 eligible patients of acute coronary
syndrome (intervention group, n = 50 and standard care group,
n = 50). About half (49%) of the patients had an ST elevation
myocardial infarction (STEMI) and the rest had a non-STEMI or
unstable angina. The mean age of the patients was 59.0  11
years and majority of the patients were men (84%). Details of
the baseline demographic and clinical characteristics are in
Table 1. About a ﬁfth smoked or used tobacco, half reportedudy subjects.
roup (n = 50) Intervention group (n = 50) p valuea
 10.8 57.3  10.5 0.177b
9.2–39.2) 16.0 (10.0–38.0) 0.844c
 17.4 15.8  13.9 0.503b
6.0) 20 (40.0) 0.680
2.0) 2 (4.0) 0.007
2.0) 28 (56.0) 0.161
7.1) 16 (57.1) 1.00
0.0) 10 (22.0) 0.806
0.0) 37 (74.0) 0.476
2.0) 27 (54.0) 0.418
0.0) 20 (40.0) 0.315
8.0) 28 (56.0) 0.855
4.0) 26 (52.0) 0.841
0.0) 41 (82.0) 0.799
6.0) 26 (52.0) 0.688
4.0) 16 (32.0) 0.373
.0) 3 (6.0) 0.695
4.0) 10 (20.0) 0.424
0.0) 3 (6.0) 0.460
0.0) 2 (4.0) 0.239
2.0) 9 (18.0) 0.401
0.0) 23 (46.0) 0.689
0.0) 16 (32.0) 0.171
6.0) 47 (94.0) 0.182
3.7) 43 (91.5) 0.085
6.3) 4 (8.5) 0.337
6.3) 3 (6.0) 0.182
00) 50 (100.0) 1.000
6.0) 38 (76.0) 0.270
4.0) 34 (68.0) 0.509
00.0) 49 (98.0) 0.219
2.0) 8 (16.0) 0.443
.0) 3 (6.0) 0.695
, coronary artery bypass grafts; RAS, renin–angiotensin system.
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moderately active. Among STEMI patients 57% were throm-
bolyzed. In the month prior to hospitalization 15% reported
taking an anti-platelet agent, 48% an antihypertensive and
26% antidiabetic medication. Patients prescribed a CVD
medication prior to the hospitalization admission reported
that they forgot to take their medication more than once a
week (20%), stopped medications on their own (9%) and
reported not taking medications on time (37%). At admission
to hospital, majority of patients were physical inactive (81%)
and on unhealthy diet (high fat 77%, high salt 58% and low ﬁber
57%) while 21% were smokers or used tobacco. Before
discharge coronary revascularization was performed in 90%
(percutaneous coronary intervention 79%, bypass surgery
11%). At discharge the prescription pattern in the study cohort
was: any antiplatelet 100%, dual antiplatelets 93%, b-blockers
71%, RAS inhibitors (ACEI or ARB) 71% and statins 99%. There
was no signiﬁcant difference in intervention and control
groups in use of cardiovascular medications at baseline
(Table 1).
Follow-up was performed according to the protocol in both
intervention and control groups and details of all the patients
were obtained periodically. At the end of 12 months,
50 patients in the intervention group and 48 in control group
were evaluated (2 patients died in the interim). Proportion of
patients receiving cardioprotective drugs (antiplatelets,
b-blockers, RAS inhibitors, and statins) at baseline, 12 months
and 24 months is shown in Fig. 1. While almost all the patients
were on antiplatelet agents or statins at discharge, a lower
proportion were on b-blockers and RAS blockers. Attrition is
observed in both intervention and control groups over time
and the use is signiﬁcantly greater in intervention group at
12 as well as 24 months (Fig. 1). At the end of 12 months, in
intervention vs control group, adherence deﬁned as >80% ofFig. 1 – Use of various cardioprotective drugs (anti-platelets, b blo
at 12 months and 24 months in intervention and control groupsdrug use (among those prescribed a particular medication) to
antiplatelets use was 92.0% vs 77.1% ( p = 0.040), b blockers in
97.2% vs 90.3% ( p = 0.231), RAS inhibitors (ACEI or ARB) in 95.1%
vs 82.3% ( p = 0.074) and statins in 94.0% vs 70.8% ( p = 0.002).
Patients taking all the four medications, derived using CMAS,
were 93.3% in intervention group vs 86.9% in the control group
(p = 0.431) (Table 2). At the end of 12 months the average
monthly consumption (mean  1SD, %) of medication (pills
taken/prescribed) in intervention vs control group were
antiplatelets in 95.0  4.2 vs 84.1  10.5 (p < 0.001), b blockers
in 95.2  5.1 vs 84.2  11.0 (p < 0.001), RAS inhibitors in 94.8 
4.6 vs 82.5  13.1 (p < 0.001), and statins in 93.7  8.3 vs 83.1 
12.4 ( p < 0.001) (Table 2).
In both intervention and control groups, adherence
decreased over the next 12 months of passive follow-up
(Table 2). 3 patients were lost to follow-up (2 intervention,
1 control) and 3 more patients in the control group died. At the
end of 24 months, the intervention group had signiﬁcantly
greater adherence to antiplatelets use 83.3% vs 40.9%
( p < 0.001), b blockers 84.8% vs 45.0% ( p = 0.002), RAS blockers
89.5% vs 46.1% ( p < 0.001), and statins 87.5% vs 29.5%
( p < 0.001) (Table 2). The percent monthly consumption was
also greater in the intervention vs control group to antiplate-
lets 88.3  7.5 vs 79.8  8.1, bblockers 86.5  10.1 vs 75.8  11.6,
RAS blockers 87.8  8.8 vs 77.8 + 9.3 and statins 87.0 + 11.8 vs
77.2 + 9.4 (all p values <0.001) (Table 2).
We also evaluated adherence to healthy lifestyles at 12 and
24 months (Fig. 2). In intervention vs control groups smoking
prevalence at 12 months was 0.0% vs 12.5% ( p = 0.002) and 4.2%
vs 20.5% at 24 months (p = 0.010). Moderate or greater regular
physical activity at 12 months was 96.0% vs 50.0% ( p < 0.001)
and 24 months was 37.5% vs 34.1% ( p = 0.733). Median healthy
diet score at 12 months was 5.0 vs 3.0 and 24 months was 4.0 vs
2.0) (p < 0.001). Differences in speciﬁc dietary intake patternsckers, RAS (renin–angiotensin system) blockers and statins)
.
Table 2 – Adherence to various medicines in control and intervention groups at 12 and 24 months.
Drug class Discharge At 12 months At 24 months
Control
(n = 50)
Intervention
(n = 50)
Control
(n = 48)
Intervention
(n = 50)
p
value*
Control
(n = 44)
Intervention
(n = 48)
p
valuea
Antiplatelets Prescribed 50 50 48 50 44 48
Adherent >80% (n, %) 37 (77.1) 46 (92.0) 0.040 18 (40.9) 40 (83.3) <0.001
Average consumption % – – 84.1  10.5 95.0  4.2 <0.001 79.8  8.1 88.3  7.5 <0.001
b blockers Prescribed 37 34 31 36 20 33
Adherent >80% (n,%) 28 (90.3) 35 (97.2) 0.231 9 (45.0) 28 (84.8) 0.002
Average consumption % 84.2  11.0 95.2  5.1 <0.001 75.8  11.6 86.5  10.1 0.001
RAS blockers Prescribed 33 38 34 41 26 38
Adherent >80% (n, %) 28 (82.4) 39 (95.1) 0.074 12 (46.1) 34 (89.5) <0.001
Average consumption % 82.5  13.1 94.8  4.6 <0.001 77.8  9.3 87.8  8.8 <0.001
Statins Prescribed 50 49 48 50 44 48
Adherent >80% (n, %) 34 (70.8) 47 (94.0) 0.002 13 (29.5) 42 (87.5) <0.001
Average consumption % 83.1  12.4 93.7  8.3 <0.001 77.2  9.4 87.0  11.8 <0.001
All four drugs Prescribed 29 28 23 30 18 28
Adherent >80% (n, %) 20 (86.9) 28 (93.3) 0.431 8 (44.4) 24 (85.7) 0.003
Average consumption % 76.2  18.8 92.6  5.4 <0.001 66.6  17.4 76.5  17.0 0.015
Numbers in parentheses are percent; Values  indicate 1 SD; RAS, renin–angiotensin system.
a p values derived using x2 test for ordinal variables and t-test for continuous variables.
Fig. 2 – Adherence to healthy lifestyles (smoking, high fat diet, high fruits and vegetables consumption and regular physical
activity) in control and intervention groups at 12 and 24 months.
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respectively, were high fat diet 16.0 vs 25.0 (p = 0.269) and
29.2 vs 47.7 ( p = 0.067), high calorie food 14.0 vs 27.1 ( p = 0.108)
and 27.1 vs 38.6 (p = 0.237), high salt diet 12.0 vs 29.2 ( p = 0.035)
and 22.9 vs 40.9 ( p = 0.063) and low fruits and vegetable intake
16 vs 43.8 (p = 0.002) and 56.3 vs 63.0 (p = 0.342) (Table 3).
In the intervention vs control groups, at 12 months,
signiﬁcantly lower values were observed for mean systolic
BP (121.2 vs 129.3 mmHg, p < 0.001), diastolic BP (79.9 vs83.8 mmHg, p < 0.001), body mass index (23.6 vs 25.8 kg/m2,
p = 0.006), waist:hip ratio (0.95 vs 0.99, p < 0.001), total
cholesterol (152.7 vs 176.7 mg/dL, p = 0.008), triglycerides
(122.1 vs 152.3 mg/dL, p = 0.006) and LDL cholesterol (92.2 vs
106.3 mg/dL, p = 0.020) (Table 3). At 24-month follow-up the
mean systolic BP and body-mass index increased but signiﬁ-
cant difference was maintained in intervention vs control
group for systolic BP (124.9 vs 135.9 mmHg, p < 0.001), diastolic
BP (81.9 vs 86.1 mm Hg, p < 0.001) and body mass index (24.2 vs
Table 3 – Changes in lifestyle factors, physiological factors and clinical outcomes at 12- and 24-month follow-up.
12 months 24 months
Control group
(n = 48)
Intervention
group (n = 50)
p
value
Control
group (n = 44)
Intervention
group (n = 48)
p
value
Lifestyle factorsa
Smoking 6 (12.5) 0 (0.0) 0.002 9 (20.5) 02 (4.2) 0.010
High fat intake 12 (25.0) 8 (16.0) 0.269 21 (47.7) 14 (29.2) 0.067
High salt intake 14 (29.2) 6 (12.0) 0.035 18 (40.9) 11 (22.9) 0.064
High calorie intake 13 (27.1) 7 (14.0) 0.108 17 (38.6) 13 (27.1) 0.238
Low ﬁber intake 8 (16.7) 07 (14.0) 0.714 21 (47.7) 18 (37.5) 0.321
Low fruit/veg intake 21 (43.8) 08 (16.0) 0.003 29 (65.9) 27 (56.3) 0.237
Physical active 24 (50.0) 48 (96.0) <0.001 15 (34.1) 18 (37.5) 0.733
Physical and biochemical factorsb
Systolic BP 129.3  8.0 121.2  5.4 <0.001 135.4  10.8 124.9  6.1 <0.001
Diastolic BP 83.8  5.7 79.9  2.1 <0.001 86.1  6.4 81.9  2.5 <0.001
Heart rate 78.5  7.4 74.9  3.9 0.003 – –
Body mass index 25.8  4.3 23.6  3.0 0.006 26.1  3.1 24.2  2.7 0.002
Waist circumference 92.2  17.0 90.5  8.5 0.521 – –
Waist:hip ratio 0.99  0.05 0.95  0.03 <0.001 – –
Cholesterol 176.7  49.9 152.7  37.5 0.008 – –
Triglyceride 152.3  61.2 122.1  44.0 0.006 – –
HDL cholesterol 37.2  5.4 39.6  9.5 0.139 – –
LDL cholesterol 106.3  28.7 92.2  29.8 0.020 – –
Clinical outcomesa
Mortality 2 (4.0) Nil 0.084 3 (6.2) Nil 0.032
Hospitalization 4 (8.3) 3 (6.0) 0.680 9 (20.4) 7 (14.6) 0.654
BP, blood pressure.
a Comparison using x2 test.
b Comparison using t-test.
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 8 3 2 – 8 4 083826.1 kg/m2, p = 0.002) (Table 3). We performed a sensitivity
analysis comparing changes in systolic BP, body mass index
and LDL cholesterol in patients adherent vs non-adherent to
therapies at 12 months in both intervention and control
groups. In intervention group the decline in systolic
BP in adherent vs non-adherent groups was 7.4  17.9
vs 1.5  6.3 mmHg ( p < 0.001) and in control group was
3.7 + 16.6 vs 2.8 + 15.8 mmHg ( p = 0.10). Change in body
mass index in adherent vs non-adherent in intervention
group was 2.20  0.86 vs 1.65  0.34 kg/m2 ( p < 0.001) and
in control group was 0.49  1.02 vs 0.47  0.51 ( p = 0.1).
LDL cholesterol also declined more in adherent vs non-
adherent in intervention group (38.1  35.2 vs 5.2 
73.5 mg/dL, p < 0.001) and not in control group (18.2 
20.8 vs 20.8  34.6 mg/dL, p = 0.1). At the end of study
period, cumulative incidence of deaths or hospitalization in
intervention vs control groups was 3 vs 6 ( p = 0.294) at
12 months and 7 vs 12 (p = 0.218) at 24 months.
4. Discussion
This open-label randomized trial shows that non-physician
health worker led educational intervention improves adherence
to cardioprotective medications and healthy lifestyles in
patients with ACS following hospital discharge. We found that
intervention signiﬁcantly improved adherence to drug thera-
pies as well as lifestyle changes at 12 months of active
intervention. The beneﬁcial effects were sustained during
passive follow-up for further 12 months although there was
signiﬁcant attrition in adherence to drugs and healthy lifestyles.There are limited studies that have focused on improving
medication adherence among patients following ACS hospi-
talization using NPHWs or CHWs.23–25 Most of the studies have
used either pharmacist-based approaches,24–29 individual
empowerment,30–33 or multifacorial approaches.34–37 In the
Netherlands, 754 ACS patients from 11 sites were randomized
to a nurse coordinator prevention program with four outpa-
tient visits aimed to improving lifestyle and medication
adherence over one year. This trial (RESPONSE) demonstrated
a 17.4% ( p = 0.021) risk reduction as measured by a coronary
risk evaluation score.27 Better adherence to drugs and to LSM
led to reductions in heart rate, systolic BP and body mass index
at one year. Smith et al. demonstrated that mailed commu-
nications to patients after myocardial infarction discharge
improved adherence to b-blockers by 4.3%.30 Ho et al.
evaluated a multifactorial approach for patient education
led by pharmacists to evaluate adherence to evidence based
medications in a study of 253 patients discharged after ACS in
the United States.37 The interventions increased adherence to
medications in the year after discharge (89.3% in intervention
group vs 73.9% in control group, p = 0.003). Similar to our study,
the interventions improved adherence to RAS blockers and
statins. Unlike our ﬁndings there was no improvement in BP
and LDL cholesterol levels.
Economic analyses of the studies in developed countries
suggest a cost-saving with appropriate secondary preven-
tion.28 However, all these studies have been performed in
developed countries and evaluated trained health workers,
e.g., nurses and pharmacists, or used multiple strategies
(NPHWs as well as reminders, voice messaging and eliminat-
ing insurance co-payments) and demonstrated modest effects
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 8 3 2 – 8 4 0 839in improving adherence and reducing risk levels. The health
systems, patient characteristics and the challenges in India
are, however, different from those observed in developed
countries and these studies may not be applicable to India or
other developing countries.4 We used a health worker and the
results have shown signiﬁcant improvement in adherence to
lifestyles and pharmatherapy at 12 months of intervention
which is similar to an earlier study in rural Andhra Pradesh.38
Uniquely, our study shows that the beneﬁcial effects of this
intervention last for a further 12 months showing the legacy
effect of our intervention. This legacy effect is similar to long-
term protective effects of pharmacological interventions in
diabetes and hypercholesterolemia and demonstrates that
even non-pharmacological interventions have similar bene-
ﬁts.
The overall adherence rate in our study at one year was
more than 90%. This is probably due to the quality of service
at the private health care center chosen for the study as well
as the motivation level and high education status of the
included patients. A very high rate of coronary interventions
is observed in our study (90%) compared to previous Indian
registries (CREATE 7%, Kerala ACS 12%).5,6 It is well known
that patients who had coronary interventions have better
adherence to drug and lifestyle measures, especially
following an ACS.23 NPHW interventions led to high level
of adherence to evidence based medications by identifying
barriers related to medications (lack of knowledge, cost of
drugs, drug side effects and lack of ﬁnancial support) and by
helping the patient ﬁnd acceptable strategies to overcome
them by being a ‘‘health champion’’. We observed improve-
ments in all lifestyle parameters in the intervention group.
This is likely due to enhanced awareness, support from
family and the persistence of the interventions to overcome
the barriers. Moreover, we included all patients who
consented to participate in the study regardless of their
prior adherence behavior and able to comply with the
requirements of the interventions, including being able to
make the follow-up visits. This could have introduced a
selection bias among patients and may explain the high
rates of adherence to medications in both groups. High rates
of adherence to drug therapies reﬂect the type of hospitals
and quality of physicians, both of which can positively bias
the adherence rates. While the medication adherence was
evaluated by visual calendar marking patients may still
have exaggerated their compliance and this is also a study
limitation. We did not use other tools such as pill count,
purchase bills or patient diary to document adherence as
these likely provide lower speciﬁcity as compared to the
tools that we designed.
Additional limitations exist in this study. We physically
followed up the patients for 12 months and contacted
telephonically at 24 month after hospital discharge. It could
be important to continue the follow-up of these patients to
assess clinical outcomes, however, the sample size is not
powered for these measures. Secondly, our intervention
included multiple components (physician, hospital counsel-
ling, NPHW and family members), all of which have been
shown to contribute to improve adherence to medication and
lifestyles.9,20,23,25 Thirdly, our study was conducted within a
single non-governmental tertiary care cardiac center and it isnot clear whether these results can be replicated in other
health care settings in India. And ﬁnally, although declines in
smoking and other lifestyle measures achieved statistical
signiﬁcance in the intervention group, we are not sure whether
these changes would sustain long term as shown by signiﬁcant
attritions (Fig. 2).
In India CVD mortality can be reduced by creation of better
healthcare delivery systems and use of NPHW for NCD
management.2,39 Our study demonstrates that non-physician
health workers (CHWs) can improve optimal use of evidence-
based medications and adequate LSMs following ACS. Use of
mobile health technologies to complement efforts of trained
NPHWs with lesser number of clinic and home visits may be
more effective in improving adherence.39 Additional studies
are needed to assess the association between adherence and
clinical outcomes in a larger patient sample with long term
follow-up. Our experience and the tools developed for
interventions can be adapted and used in similar other
hospital settings in India to improve outcomes after an acute
coronary event.
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